MA53138B1 - Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) - Google Patents

Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2)

Info

Publication number
MA53138B1
MA53138B1 MA53138A MA53138A MA53138B1 MA 53138 B1 MA53138 B1 MA 53138B1 MA 53138 A MA53138 A MA 53138A MA 53138 A MA53138 A MA 53138A MA 53138 B1 MA53138 B1 MA 53138B1
Authority
MA
Morocco
Prior art keywords
ikzf2
treatment
zinc finger
oxoisoindoline
piperidine
Prior art date
Application number
MA53138A
Other languages
English (en)
Other versions
MA53138A (fr
Inventor
Noel Marie-France Thomsen
Michael Scott Visser
Simone Bonazzi
Artiom Cernijenko
Claire Adcock
Philip Lam
Kathryn Taylor Linkens
Hasnain Ahmed Malik
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/IB2019/055804 external-priority patent/WO2020012334A1/fr
Publication of MA53138A publication Critical patent/MA53138A/fr
Publication of MA53138B1 publication Critical patent/MA53138B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé de formule (i') : ou un sel, un hydrate, un solvate, un promédicament, un stéréoisomère ou un tautomère pharmaceutiquement acceptable de celui-ci, dans laquelle rx, x1, x2, et r1 sont tels que définis dans la description, et son utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2).
MA53138A 2018-07-10 2019-07-08 Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2) MA53138B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695920P 2018-07-10 2018-07-10
PCT/IB2019/055804 WO2020012334A1 (fr) 2018-07-10 2019-07-08 Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2)

Publications (2)

Publication Number Publication Date
MA53138A MA53138A (fr) 2021-05-19
MA53138B1 true MA53138B1 (fr) 2023-10-31

Family

ID=75905122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53138A MA53138B1 (fr) 2018-07-10 2019-07-08 Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2)

Country Status (2)

Country Link
AR (1) AR116110A1 (fr)
MA (1) MA53138B1 (fr)

Also Published As

Publication number Publication date
MA53138A (fr) 2021-05-19
AR116110A1 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
MA49952B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
CR20200588A (es) Compuestos novedosos
GEAP202315746A (en) Protein tyrosine phosphatase inhibitors
MX2020014098A (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
MA30433B1 (fr) Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA45888A1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2021007258A (es) Composiciones de esparsentan amorfas.
FR3066761B1 (fr) Nouveaux composes inhibiteurs des canaux ioniques
MA50069B1 (fr) Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
PH12022550983A1 (en) Novel substituted condensed ring compound
EA202191349A1 (ru) 1,3,4-оксадиазолон и фармацевтический препарат
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer
MA41311B1 (fr) Peptides antagonistes du cgrp